These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30447931)

  • 1. Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials.
    D'Agostino M; De Paoli L; Conticello C; Offidani M; Ria R; Petrucci MT; Spada S; Marcatti M; Catalano L; Gilestro M; Guglielmelli T; Baldini L; Gamberi B; Rizzi R; De Sabbata G; Di Renzo N; Patriarca F; Pezzatti S; Siniscalchi A; Ribolla R; Palumbo A; Montefusco V; Nagler A; Boccadoro M; Gay F
    Crit Rev Oncol Hematol; 2018 Dec; 132():9-16. PubMed ID: 30447931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
    Palumbo A; Gay F; Cavallo F; Di Raimondo F; Larocca A; Hardan I; Nagler A; Petrucci MT; Hajek R; Pezzatti S; Delforge M; Patriarca F; Donato F; Cerrato C; Nozzoli C; Yu Z; Boccadifuoco L; Caravita T; Benevolo G; Guglielmelli T; Vincelli D; Jacques C; Dimopoulos MA; Ciccone G; Musto P; Corradini P; Cavo M; Boccadoro M
    J Clin Oncol; 2015 Oct; 33(30):3459-66. PubMed ID: 26282661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.
    Gay F; Oliva S; Petrucci MT; Montefusco V; Conticello C; Musto P; Catalano L; Evangelista A; Spada S; Campbell P; Ria R; Salvini M; Offidani M; Carella AM; Omedé P; Liberati AM; Troia R; Cafro AM; Malfitano A; Falcone AP; Caravita T; Patriarca F; Nagler A; Spencer A; Hajek R; Palumbo A; Boccadoro M
    Leukemia; 2017 Aug; 31(8):1727-1734. PubMed ID: 28008174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.
    Cerrato C; Di Raimondo F; De Paoli L; Spada S; Patriarca F; Crippa C; Mina R; Guglielmelli T; Ben-Yehuda D; Oddolo D; Nozzoli C; Angelucci E; Cascavilla N; Rizzi R; Rocco S; Baldini L; Ponticelli E; Marcatti M; Cangialosi C; Caravita T; Benevolo G; Ria R; Nagler A; Musto P; Tacchetti P; Corradini P; Offidani M; Palumbo A; Petrucci MT; Boccadoro M; Gay F
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1357-1366. PubMed ID: 29675792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
    J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
    Sonneveld P; Schmidt-Wolf IG; van der Holt B; El Jarari L; Bertsch U; Salwender H; Zweegman S; Vellenga E; Broyl A; Blau IW; Weisel KC; Wittebol S; Bos GM; Stevens-Kroef M; Scheid C; Pfreundschuh M; Hose D; Jauch A; van der Velde H; Raymakers R; Schaafsma MR; Kersten MJ; van Marwijk-Kooy M; Duehrsen U; Lindemann W; Wijermans PW; Lokhorst HM; Goldschmidt HM
    J Clin Oncol; 2012 Aug; 30(24):2946-55. PubMed ID: 22802322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
    Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
    Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery, Development, and clinical applications of bortezomib.
    Jung L; Holle L; Dalton WS
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
    Morabito F; Bringhen S; Larocca A; Wijermans P; Victoria Mateos M; Gimsing P; Mazzone C; Gottardi D; Omedè P; Zweegman S; José Lahuerta J; Zambello R; Musto P; Magarotto V; Schaafsma M; Oriol A; Juliusson G; Cerrato C; Catalano L; Gentile M; Isabel Turel A; Marina Liberati A; Cavalli M; Rossi D; Passera R; Rosso S; Beksac M; Cavo M; Waage A; San Miguel J; Boccadoro M; Sonneveld P; Palumbo A; Offidani M
    Am J Hematol; 2014 Apr; 89(4):355-62. PubMed ID: 24273190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
    Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
    Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
    Huang H; Zhou L; Peng L; Fu W; Zhang C; Hou J
    Leuk Res; 2014 Sep; 38(9):1048-54. PubMed ID: 25052306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
    Mateos MV; Goldschmidt H; San-Miguel J; Mikhael J; DeCosta L; Zhou L; Obreja M; Blaedel J; Szabo Z; Leleu X
    Hematol Oncol; 2018 Apr; 36(2):463-470. PubMed ID: 29446103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany.
    Kuhr K; Wirth D; Srivastava K; Lehmacher W; Hellmich M
    Eur J Clin Pharmacol; 2016 Mar; 72(3):257-65. PubMed ID: 26671239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new standard of care in newly diagnosed multiple myeloma.
    Richardson PG
    Lancet; 2010 Dec; 376(9758):2043-4. PubMed ID: 21146204
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.
    Shang Y; Jin Y; Liu H; Ding L; Tong X; Tu H; Zang L; Lin C; Hu J; Zhou F
    Hematol Oncol; 2022 Apr; 40(2):212-222. PubMed ID: 34860428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.
    Offidani M; Corvatta L; Bringhen S; Gentili S; Troia R; Maracci L; Larocca A; Gay F; Leoni P; Boccadoro M
    Eur J Haematol; 2017 Mar; 98(3):289-295. PubMed ID: 27893171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis.
    Al Saleh AS; Visram A; Parmar H; Muchtar E; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Leung N; Go RS; Gonsalves WI; Kourelis TV; Hayman SR; Kapoor P; Gertz MA; Kyle RA; Rajkumar SV; Kumar SK
    Leuk Lymphoma; 2021 Dec; 62(12):3011-3018. PubMed ID: 34263694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
    Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
    Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.